PMV Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	38.53	109.12	173.29	361.42	73.28	30.31
Short-Term Investments	165.35	132.76	124.7	0	28.21	31.6
Cash & Cash Equivalents	203.88	241.88	297.99	361.42	101.49	61.91
Cash Growth	-15.71%	-18.83%	-17.55%	256.13%	63.93%	-
Other Current Assets	3.53	5.13	3.3	3.34	0.61	0.33
Total Current Assets	207.41	247.01	301.29	364.76	102.09	62.24
Property, Plant & Equipment	19.05	20.49	13.15	0.57	0.74	1.02
Long-Term Investments	25.51	2.5	16.91	0	0	0
Other Long-Term Assets	0.19	0.31	0.22	0.2	0.2	0.2
Total Long-Term Assets	44.74	23.3	30.28	0.77	0.94	1.22
Total Assets	252.15	270.31	331.57	365.53	103.03	63.46
Accounts Payable	3.24	3	3.19	1.61	2.84	1.04
Current Debt	0.85	0.53	0.4	0	0	0
Other Current Liabilities	9.94	7.31	8.63	4.8	1.69	1.29
Total Current Liabilities	14.03	10.83	12.22	6.41	4.52	2.33
Long-Term Debt	12.43	13.45	10.79	0	0	0
Other Long-Term Liabilities	0	0	0	0	0.05	0.04
Total Long-Term Liabilities	12.43	13.45	10.79	0	0.05	0.04
Total Liabilities	26.46	24.28	23.01	6.41	4.57	2.37
Total Debt	13.29	13.98	11.19	0	0	0
Debt Growth	-4.94%	24.86%	-	-	-	-
Retained Earnings	-310	-241.04	-167.73	-109.88	-75.44	-50.09
Comprehensive Income	0.22	-0.45	-0.08	0	-0	-0.01
Shareholders' Equity	225.69	246.03	308.56	359.12	-70.47	-46.14
Net Cash / Debt	190.59	227.9	286.79	361.42	101.49	61.91
Net Cash / Debt Growth	-16.37%	-20.53%	-20.65%	256.13%	63.93%	-
Net Cash Per Share	3.97	5.00	6.35	25.16	33.44	20.55
Working Capital	193.38	236.17	289.07	358.35	97.57	59.91
Book Value Per Share	4.70	5.40	6.84	25.00	-23.22	-15.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).